Micromet Signs Deals With Bayer And Lonza | December 7, 2009 Issue - Vol. 87 Issue 49 | Chemical & Engineering News
Volume 87 Issue 49 | p. 23 | Concentrates
Issue Date: December 7, 2009

Micromet Signs Deals With Bayer And Lonza

Department: Business
Keywords: antibodies, drug development, contract manufacturing

German biotech firm Micromet will work with Bayer Schering Pharma to develop a new antibody against an undisclosed solid tumor target. Micromet’s BiTE antibodies help direct the body’s cell-killing T cells against tumor cells. The two companies will collaborate through Phase I clinical trials, after which Bayer will assume control. Bayer will pay Micromet $7.5 million up front and up to $430 million in milestone payments. Separately, Micromet has hired Lonza to conduct process development and manufacturing of blinatumomab, an antibody in clinical studies for treating hematologic cancers.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment